Labormed achieves 90% of H1 target

Generic drugs manufacturer Labormed Bucharest has posted turnover of more than 8 million euros for the first half of this year, representing around 90% of its six-month target of 9 million euros. The pharmaceuticals market took a plunge in the second quarter after consumption had increased by about 30% in the first three months of the year, compared with the period time in 2004, market players say. “The results obtained were largely due to the structure of the company”s portfolio, more than 50% of which is made up of cardiovascular drugs. The cardiovascular segment has maintained a constant trend lately,” said Marcian Gavrilescu, the company”s general manager. Besides cardiovascular drugs, the company also makes drugs for treating conditions of the central nervous system (25% of its production), as well as for respiratory and digestive conditions. “The cardiovascular segment reached 170 million euros in the year to the end of March, accounting for some 16% of total market value,” explained Gabriel Cernica, Labormed”s marketing manager. According to its own estimates, the company accounts for 6.3% of the cardiovascular segment by value. ZF